scholarly journals Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic

2019 ◽  
Vol 6 (4) ◽  
Author(s):  
Sarah E Sansom ◽  
Jonathan Martin ◽  
Oluwatoyin Adeyemi ◽  
Kerianne Burke ◽  
Crystal Winston ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Clinical Experience ◽  
Transient Elastography ◽  
Controlled Attenuation Parameter ◽  
Attenuation Parameter ◽  
Immunodeficiency Virus ◽  
Hcv Coinfection

scholarly journals Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy

2020 ◽  
Vol 7 (5) ◽  
Author(s):  
Yanina Ghiglione ◽  
María Laura Polo ◽  
Alejandra Urioste ◽  
Ajantha Rhodes ◽  
Alejandro Czernikier ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiretroviral Therapy ◽  
Direct Acting Antivirals ◽  
Hiv Persistence ◽  
Hiv Rna ◽  
Immunodeficiency Virus ◽  
Hcv Coinfection ◽  
Direct Acting

Abstract Background Hepatitis C virus (HCV) coinfection among people with human immunodeficiency virus (HIV) might perturb immune function and HIV persistence. We aimed to evaluate the impact of HCV clearance with direct-acting antivirals (DAAs) on immune activation and HIV persistence in HIV/HCV-coinfected individuals on antiretroviral therapy (ART). Methods In a prospective observational study, ART-treated participants with HIV/HCV coinfection received sofosbuvir/daclatasvir ± ribavirin (n = 19). Blood samples were collected before DAA therapy, at the end of treatment, and 12 months after DAA termination (12MPT). T- and natural killer (NK)-cell phenotype, soluble plasma factors, cell-associated (CA)-HIV deoxyribonucleic acid (DNA) forms (total, integrated, 2LTR), CA-unspliced (US) and multiple-spliced ribonucleic acid (RNA), and plasma HIV RNA were evaluated. Results Hepatitis C virus clearance was associated with (1) a downmodulation of activation and exhaustion markers in CD4+, CD8+ T, and NK cells together with (2) decreased plasma levels of Interferon gamma-induced protein 10 (IP10), interleukin-8 (IL-8), soluble (s)CD163 and soluble intercellular adhesion molecule (sICAM). Cell-associated US HIV RNA was significantly higher at 12MPT compared to baseline, with no change in HIV DNA or plasma RNA. Conclusions Elimination of HCV in HIV/HCV-coinfected individuals alters immune function and the transcriptional activity of latently infected cells. This report provides insights into the effects of HCV coinfection in HIV persistence and regards coinfected subjects as a population in which HIV remission might prove to be more challenging.

Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: A paired liver biopsy study

2007 ◽  
Vol 46 (4) ◽  
pp. 613-619 ◽  
Author(s):  
Maribel Rodríguez-Torres ◽  
José F. Rodríguez-Orengo ◽  
Carlos F. Ríos-Bedoya ◽  
Alberto Fernández-Carbia ◽  
Acisclo M. Marxuach-Cuétara ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Progression Rate ◽  
Fibrosis Progression ◽  
Immunodeficiency Virus

scholarly journals Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Marianne Martinello ◽  
Gregory J. Dore ◽  
Jasmine Skurowski ◽  
Rohan I. Bopage ◽  
Robert Finlayson ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Major Advance ◽  
Potential Ddis ◽  
Direct Acting Antiviral ◽  
Immunodeficiency Virus ◽  
Hcv Coinfection ◽  
Direct Acting ◽  
Prescribing Information

AbstractBackground.  Interferon-free direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) provide a major advance in clinical management, including in human immunodeficiency virus (HIV)/HCV coinfection. Drug-drug interactions (DDIs) with combination antiretroviral therapy (cART) require consideration. This study aimed to characterize the cART regimens in HIV/HCV-coinfected individuals and assess the clinical significance of DDIs with DAAs in a real-world cohort.Methods.  This analysis included participants enrolled in CEASE-D, a prospective cohort of HIV/HCV-coinfected individuals in Sydney, Australia, between July 2014 and December 2015. A simulation of potential DDIs between participants' cART and interferon-free DAA regimens was performed using www.hep-druginteractions.org and relevant prescribing information.Results.  In individuals on cART with HCV genotype (GT) 1 and 4 (n = 128), category 3 DDIs (contraindicated or not recommended) were noted in 0% with sofosbuvir/ledipasvir, 0% with sofosbuvir plus daclatasvir, 17% with sofosbuvir/velpatasvir, 36% with ombitasvir/paritaprevir/ritonavir ± dasabuvir, 51% with grazoprevir/elbasvir, and 51% with sofosbuvir plus simeprevir; current cART regimens were suitable for coadministration in 100%, 100%, 73%, 64%, 49%, and 49%, respectively. In individuals with HCV GT 2 or 3 (n = 53), category 3 DDIs were evident in 0% with sofosbuvir plus daclatasvir, 0% with sofosbuvir and ribavirin, and 13% with sofosbuvir/velpatasvir; current cART regimens were suitable in 100%, 100%, and 81%, respectively.Conclusions.  Potential DDIs are expected and will impact on DAA prescribing in HIV/HCV coinfection. Sofosbuvir in combination with an NS5A inhibitor or ribavirin appeared to be the most suitable regimens in this cohort. Evaluation of potential DDIs is required to prevent adverse events or treatment failure.

scholarly journals Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Sebhat Erqou ◽  
Arpan Mohanty ◽  
Pashtoon Murtaza Kasi ◽  
Adeel A. Butt
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hcv Treatment ◽  
Predictors Of Mortality ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Immunodeficiency Virus ◽  
All Cause Mortality ◽  
Hcv Coinfection

Background. Understanding the predictors of mortality in individuals with human immunodeficiency virus and hepatitis C virus (HIV/HCV) coinfection can be useful in management of these patients. Methods. We used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) for these analyses. Multivariate Cox-regression models were used to determine predictors of mortality. Results. Among 8,039 HIV infected veterans, 5251 (65.3%) had HCV coinfection. The all-cause mortality rate was 74.1 (70.4–77.9) per 1000 person-years (PY) among veterans with HIV/HCV coinfection and 39.8 (36.3–43.6) per 1000 PY for veterans with HIV monoinfection. The multivariable adjusted hazard ratio (95% confidence interval) of all-cause mortality for HCV infection was 1.58 (1.36–1.84). Positive predictors of mortality included decompensated liver disease (2.33 (1.98–2.74)), coronary artery disease (1.74 (1.32–2.28)), chronic kidney disease (1.62 (1.36–1.92)), and anemia (1.58 (1.31–1.89)). Factors associated with reduced mortality included HCV treatment (0.41 (0.27–0.63)) and higher CD4 count (0.90 (0.87–0.93) per 100 cells/μL higher count). Data were insufficient to make informative analyses of the role of HCV virologic response. Conclusion. HCV coinfection was associated with substantial increased risk of mortality among HIV infected veterans. HCV treatment was associated with significantly lower risk of mortality.

scholarly journals Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs

Hepatology ◽  
2014 ◽  
Vol 59 (3) ◽  
pp. 767-775 ◽  
Author(s):  
Monica A. Konerman ◽  
Shruti H. Mehta ◽  
Catherine G. Sutcliffe ◽  
Trang Vu ◽  
Yvonne Higgins ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Prospective Analysis ◽  
Virus Hepatitis ◽  
Fibrosis Progression ◽  
Immunodeficiency Virus

scholarly journals Evaluating the Effectiveness of the AIDS Education and Training Center (AETC) National Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Curriculum

2021 ◽  
Vol 8 ◽  
pp. 238212052110411
Author(s):  
Waridibo E Allison ◽  
Aro N Choi ◽  
Keito Kawasaki ◽  
Trisha V Melhado
Keyword(s):  
Health Care ◽  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Health Care Providers ◽  
Therapeutic Option ◽  
Aids Education ◽  
Care Providers ◽  
Immunodeficiency Virus ◽  
Hcv Coinfection

Background People with human immunodeficiency virus (PWHIV) who have hepatitis C virus (HCV) coinfection are at a higher risk of progression of liver disease than the general population. Direct acting antivirals provide a therapeutic option for HCV cure, however access to HCV specific care for PWHIV can be challenging. A paucity of specialist providers is a barrier to this care. Objectives This study aims to assess knowledge gained about HIV/HCV coinfection among health care providers. Methods AIDS Education Training Centers (AETC) have developed a modular national HIV/HCV coinfection curriculum consisting of a free selfdirected online curriculum to educate health care providers, including nonspecialist providers, involved in the care of PWHIV on HCV care and management. The effectiveness of this curriculum was evaluated with pre and post module assessment completion by learners compared with a paired t-test. Results 716 people received links to the curriculum and 277 modules were completed by 221 unique individuals. 86% completed one module, 9% complete 2 modules, and the remaining 5% completed between 3 and all 6 modules. There were statistically significant increases in knowledge in the epidemiology module.

scholarly journals HUMAN IMMUNODEFICIENCY VIRUS-HEPATITIS C VIRUS COINFECTION: A REVIEW ON NECESSITY OF DIETARY COMPOUNDS FOR ANTIRETROVIRAL THERAPY

2018 ◽  
Vol 11 (8) ◽  
pp. 30
Author(s):  
Suganya Selvaraj ◽  
Shanmughavel Piramanayagam
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiretroviral Therapy ◽  
Adverse Effects ◽  
Liver Damage ◽  
Synthetic Drugs ◽  
Cell Counts ◽  
Immunodeficiency Virus ◽  
Hcv Coinfection

Human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection is a major health problem around worldwide. One-third of the HIV-infected patients suffer from chronic hepatitis (HCV). The risk factors of coinfected patients are very high while compared to the monoinfected patients; they are having higher HCV viral load is associated with a severe liver damage. The use of highly active antiretroviral therapy (HAART) dramatically increases the survival of HIV/HCV-coinfected patients by preventing the depletion of CD4 cell counts and delaying the progression of fibrosis which reduces the complications related to end-stage liver damage. Reverse-transcriptase inhibitors and protease inhibitors are very commonly used drugs for the treatment of coinfection. Combination drugs and synthetic drugs are playing a pivotal role in the coinfection therapy. Under HAART, the coinfected patients are affected by many adverse effects such as mitochondrial toxicity, hypersensitivity, and lipodystrophy syndrome. However, the adverse effects of most herbal drugs are relatively less frequent when the drugs are used properly compared with synthetic drugs; it may help to protect the patients from severe adverse effects. This review collates to the importance of plant-derived drugs for the treatment of HIV-HCV coinfection.

Sign in / Sign up

Export Citation Format

Share Document